

Please complete the ABSTRACT TEMPLATE online, for Biomed 2023 Company Presentations

ABSTRACT TEMPLATE: CHECKLIST AND INSTRUCTIONS

Company name EXOSOMM* Website <https://www.exosomm.com/> *

CEO name Netta Granot - * Cell phone number +972-54-6765638 *

Select a CATEGORY: Biotech/Pharma *

Select up to two SESSIONS per abstract from the list below *

10. Let food be thy medicine and medicine be thy food

Executive Summary / Investment Rational

EXOSOMM is developing nutritional solutions, containing exosomes, immune-effective nanoparticles, for a variety of medical conditions.

Initial products are targeting 10 million patients with Crohn's and Colitis.

The world's pioneer team of EXOSOMM is backed by leading Israeli organizations, such as Clalit and Tnuva.

We have strong IP and pre-clinical promising evidence and are currently in the scaleup phase toward commercialization.

Core Technology

EXOSOMM's technology is harnessing a natural mechanism, originally made to protect infants' health, and uses it to treat adults with chronic diseases. Exosomes are nanoparticles naturally present in mammalian milk that protect beneficial miRNAs which we proved to have anti-inflammatory activity.

Our products are nutritional solutions that actively reduce and prevent bowel inflammation, naturally with no side adverse effects.

Product Profile/Pipeline

Our first product is a medical food with isolated milk exosomes as an active ingredient for inflammatory bowel disease patients.

With the proven efficacy of our MVP, and an environmentally friendly, natural, and cost-effective commercial production process, we are moving towards the industrialization stage, collaborating with a strategic partner.

The go-to-market plan includes partnering with global medical-food players.

Business Strategy

Due to the strong granted IP and B2B strategy, we will bring the product to the global markets and will create demand and credibility in the most cost-effective way.

The anticipated revenues are over \$150M in six years.

For the long term, we developed a platform of innovative products for various medical and health conditions, such as Diabetes and Cancer.

What's Next?

The R&D plans include scaling up the proprietary production process and the development of food applications.

Followingly, completing pre-clinical studies for the commercial standard and conducting clinical trials in IBD patients. In parallel to submission for regulatory approvals.

The current fundraising aims to enable our business plan and to build infrastructures for deepening the R&D and broadening the food-as-a-medicine concept.